This work is licensed under a
Creative Commons Attribution 4.0 International License
[1] M. Malvezzi, P. Bertuccio, F. Levi, C. La Vecchia, E. Negri. European cancer mortality predictions for the year 2013. Ann Oncol. 24 (2013) 792-800.
DOI: https://doi.org/10.1093/annonc/mdt010[2] G. Barugola, S. Partelli, S. Marcucci, N. Sartori, P. Capelli, C. Bassi, P. Pederzoli, M. Falconi. Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol. 16 (2009) 3316-3322.
DOI: https://doi.org/10.1245/s10434-009-0670-7[3] G.R. Varadhachary, E.P. Tamm, J.L. Abbruzzese, H.Q. Xiong, C.H. Crane, H. Wang, J.E. Lee, P.W. Pisters, D.B. Evans, R.A. Wolff. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 13 (2006).
DOI: https://doi.org/10.1245/aso.2006.08.011[4] M. Glanemann, B. Shi, F. Liang, X.G. Sun, M. Bahra, D. Jacob, U. Neumann, P. Neuhaus. Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J Surg Oncol 6 (2008) 123.
DOI: https://doi.org/10.1186/1477-7819-6-123[5] J.M. Laurence, P.D. Tran, K. Morarji, G.D. Eslick, V.W. Lam, C. Sandroussi. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 15 (2011).
DOI: https://doi.org/10.1007/s11605-011-1659-7[6] A. Andriulli, V. Festa, E. Botteri, M.R. Valvano, M. Koch, C. Bassi, P. Maisonneuve, P.D. Sebastiano. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 19 (2012).
DOI: https://doi.org/10.1245/s10434-011-2110-8[7] A. Shehzad, F. Wahid, Y.S. Lee. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. ArchPharm (Weinheim). 343 (2010) 489-499.
DOI: https://doi.org/10.1002/ardp.200900319[8] T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J.L. Raoul, S. Gourgou-Bourgade, C. de la Fouchardière, J. Bennouna, J.B. Bachet, F. Khemissa-Akouz, D. Péré-Vergé, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364 (2011).
DOI: https://doi.org/10.1056/nejmoa1011923[9] D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, T. Seay, S.A. Tjulandin, W.W. Ma, M.N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R.K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, X. Wei, J. Iglesias, M.F. Renschler. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369 (2013).
DOI: https://doi.org/10.1056/nejmoa1304369[10] F. Petrelli, A. Coinu, K. Borgonovo, M. Cabiddu, M. Ghilardi, V. Lonati, E. Aitini, S. Barni; Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD). FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 44 (2015).
DOI: https://doi.org/10.1097/mpa.0000000000000314[11] C. Soldà, R. Bardini, C. Sperti, G. Da Dalt, M. Gion, P. Fiduccia, F. Ursini, C. Aliberti, D. Pastorelli. Phase II study of gemcitabine and curcumin as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data Ann Oncol 26 (suppl 4) (2015).
DOI: https://doi.org/10.1093/annonc/mdv344.41